ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33947691.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0627.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activating mutations of the anaplastic lymphoma kinase (<i>ALK</i>) gene were identified in the pediatric tumor neuroblastoma, in 2008. Rapid translation of this finding into targeted neuroblastoma therapy was facilitated by the availability of ALK inhibitors developed for adult malignancies and an efficient preclinical and clinical research program.<i>See related article by Foster et al., p. 3543</i>.
Medical subject headings
- Neuroblastoma
- Receptor Protein-Tyrosine Kinases